Structure (Spironolactone 01)
Spironolactone Tablet, Film Coated
Product Images NDC 71335-2887
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 71335-2887). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Spironolactone 02)
This text is describing a medical study comparing the medication Spironolactone to a placebo over a period of 48 months. The results indicate a significant difference between the two groups, with a log-rank p-value of less than 0.001, suggesting that Spironolactone had a notable impact compared to the placebo.*
Figure 2 (Spironolactone 03)
This text appears to be a table with various medical data related to diabetes, including creatinine levels, potassium levels, and the use of Beta Blockers and Spironolactone as treatments. Additionally, the table seems to show comparisons between different treatments or conditions marked as "Spironolactone better" and "Placebo better".*
Label (Lbl713352887)
This is a medication package insert for tablets containing Spironolactone 50mg. It provides information on the dosage, storage conditions, and prescribing information. The tablets should be stored at a temperature between 20°C to 25°C (68°F to 77°F) in a tight, light-resistant container. The tablets are manufactured by Bryant Ranch Prepack, Inc. and relabeled by Frontida BioPharm, Inc.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
